Brief: Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.
30/01/2018 21:46
Jan 30 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* BELLICUM PHARMACEUTICALS ANNOUNCES CLINICAL HOLD ON
BPX-501
CLINICAL TRIALS IN THE UNITED STATES
* BELLICUM PHARMACEUTICALS INC - RECEIVED NOTICE FROM U.S.
FOOD
AND DRUG ADMINISTRATION THAT U.S. STUDIES OF BPX-501 HAVE BEEN
PLACED ON A CLINICAL HOLD
* BELLICUM PHARMACEUTICALS INC - FDA CLINICAL HOLD DOES NOT
AFFECT ONGOING BP-004 REGISTRATION TRIAL IN EUROPE
* BELLICUM PHARMACEUTICALS - STUDIES OF BPX-501 PLACED ON
CLINICAL
HOLD FOLLOWING THREE CASES OF ENCEPHALOPATHY DEEMED AS POSSIBLY
RELATED TO BPX-501
* BELLICUM PHARMACEUTICALS INC - BELLICUM IS AWAITING FORMAL
COMMUNICATIONS FROM FDA TO DETERMINE REQUIREMENTS FOR RESUMING
STUDIES
Source text for Eikon: ID:nGNXOMTPNa
Further company coverage: BLCM.O
(((Bangalore.newsroom@thomsonreuters.com;);))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview